Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Jan 24, 2024 $26.12 $26.38 $24.92 $25.06 1 413 472
Jan 23, 2024 $26.75 $26.98 $25.22 $25.79 981 196
Jan 22, 2024 $25.78 $26.98 $25.71 $26.13 1 162 587
Jan 19, 2024 $25.21 $25.60 $24.76 $25.55 1 240 710
Jan 18, 2024 $25.94 $26.00 $24.86 $25.24 1 214 504
Jan 17, 2024 $26.06 $26.82 $25.55 $25.74 1 217 176
Jan 16, 2024 $27.35 $27.35 $26.44 $26.76 1 318 281
Jan 12, 2024 $28.67 $29.52 $27.49 $27.67 1 175 232
Jan 11, 2024 $28.15 $28.60 $27.60 $28.15 1 434 007
Jan 10, 2024 $29.83 $29.83 $28.28 $28.88 1 122 771
Jan 09, 2024 $29.12 $29.95 $28.81 $29.29 1 085 461
Jan 08, 2024 $28.18 $30.08 $27.86 $30.07 1 347 055
Jan 05, 2024 $28.83 $28.94 $27.36 $28.63 1 324 437
Jan 04, 2024 $29.35 $29.70 $28.84 $29.52 1 558 366
Jan 03, 2024 $30.29 $30.74 $29.10 $29.49 1 440 101
Jan 02, 2024 $30.05 $32.34 $29.33 $30.82 1 482 824
Dec 29, 2023 $31.78 $31.91 $30.45 $30.49 1 247 273
Dec 28, 2023 $31.80 $32.35 $31.29 $31.77 1 256 862
Dec 27, 2023 $32.83 $33.31 $31.08 $31.74 1 280 694
Dec 26, 2023 $31.67 $32.64 $31.64 $32.34 1 132 810
Dec 22, 2023 $30.86 $32.68 $30.50 $31.36 1 454 692
Dec 21, 2023 $30.49 $31.12 $29.72 $30.20 1 117 701
Dec 20, 2023 $32.03 $32.19 $29.56 $29.62 1 518 735
Dec 19, 2023 $30.69 $32.42 $30.69 $32.02 1 887 369
Dec 18, 2023 $30.64 $31.47 $29.85 $30.35 1 147 174
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT